The Peril of Self-Medication
The recent case of a 55-year-old man from Gujarat, identified only as Ravi, serves as a stark warning about the dangers of using powerful weight-loss medications
without professional medical oversight. Ravi, seeking to manage his weight, opted for oral semaglutide pills, a drug primarily known for diabetes regulation but also recognized for its weight-reducing side effects. He procured these pills over-the-counter, bypassing essential medical consultations. Months later, experiencing concerns about potential side effects, he sought evaluation. During diagnostic tests, he was unexpectedly diagnosed with medullary thyroid cancer. This diagnosis was particularly concerning given his family history of the same cancer, a significant contraindication for semaglutide use. Experts emphasize that individuals with a family history of medullary thyroid carcinoma or MEN2 syndrome should strictly avoid GLP-1 receptor agonists like semaglutide due to an elevated risk, as suggested by some animal studies. The drug carries a clear warning for such individuals, necessitating careful patient selection by qualified healthcare providers. It is crucial that semaglutide is prescribed only by specialists such as diabetologists, internal medicine practitioners, or cardiologists, and never taken without explicit medical advice. Dr. Anoop Misra, chairman of Fortis C-Doc, notes a disturbing increase in self-medication cases, with instances of patients presenting for evaluation rising to one every ten days since the injectable versions became available in India, a trend likely to escalate with cheaper generic versions entering the market. These self-medicating individuals often suffer from gastrointestinal issues like nausea and vomiting, and in more severe instances, pancreatic pain.
Who Should Avoid These Drugs?
Certain health profiles necessitate a complete avoidance of GLP-1 receptor agonists like semaglutide due to significant risks. Individuals with a personal or familial history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) are at a heightened risk and must refrain from using these medications. Furthermore, pregnant women and those who are breastfeeding should not take these drugs, with recommendations to discontinue them at least two months prior to conception. A history of pancreatitis is another strong contraindication, as these medications can exacerbate inflammation of the pancreas. People suffering from severe gastrointestinal diseases, particularly gastroparesis—a condition where the stomach empties too slowly—should also steer clear. Lastly, anyone with a known severe allergic reaction, such as anaphylaxis, to GLP-1 agonists or their components must not use them. These are critical exclusionary criteria that underscore the importance of a thorough medical evaluation before considering any weight-loss drug.
Careful Monitoring Required
While some individuals must completely avoid GLP-1 receptor agonists, others require vigilant monitoring and careful consideration before and during treatment. Those with diabetic retinopathy, a vision impairment caused by diabetes, need to consult a doctor because the rapid improvement in blood sugar levels achieved by these drugs can sometimes worsen their condition temporarily. Similarly, individuals with a history of eating disorders or depression should undergo a thorough evaluation by a healthcare professional, as these drugs might impact mental health. Patients with kidney impairment, specifically an eGFR below 30, also require close observation. Advanced kidney disease can be exacerbated by the nausea, vomiting, and dehydration that may accompany GLP-1 therapy, potentially worsening renal function. The correct dosage and slow titration are paramount for safe and effective weight loss, as highlighted by Dr. V. Mohan. Incorrect dosing, as seen with a 50-year-old Chennai resident, Sangeeta, who mistakenly administered a ten-fold higher dose, can lead to severe symptoms like intense vomiting, requiring hospitalization and extensive supportive care. This underscores the necessity of medical supervision to manage potential side effects and adjust doses according to individual tolerance and response.
The Rise of Generic Versions
The increasing availability of cheaper generic versions of semaglutide has led to a significant surge in their prescription and use. These generic alternatives can be up to 90% less expensive than the original innovator molecule, making them accessible to a broader population for whom the cost was previously a barrier. Dr. Ambrish Mithal notes a definite uptick in the prescription of GLP-1 drugs with the advent of these more affordable options. While he hasn't personally encountered patients with acute adverse events in his practice, he observes individuals who initiated the medication without medical consultation but later sought advice after concerns were raised by family or friends. Although strict guidelines exist for who should prescribe these medications, enforcing these regulations proves challenging. Some physicians may feel pressured to prescribe them, knowing that if they don't, another practitioner might. However, it is imperative that these drugs are administered strictly to the intended patient population. When prescribed and monitored appropriately by qualified medical professionals, GLP-1 drugs remain a safe and effective therapeutic option for many patients, offering substantial benefits in weight management and glycemic control.
